Cirrhosis and the patient with liver disease
Why examiners ask this
The cirrhotic patient for non-hepatic surgery lets the examiner test risk stratification, multi-organ physiology and the pharmacology of drugs that need the liver. Cirrhosis touches every system: a hyperdynamic circulation, portopulmonary hypertension, hepatopulmonary syndrome, hepatorenal syndrome, encephalopathy and a coagulopathy that is not what the INR says. It stresses application of knowledge and judgment about whether to operate at all.
The 60-second answer
My first question is whether this patient should have surgery, because perioperative mortality tracks the severity of liver disease. I calculate the MELD and Child-Pugh class: Child A or MELD under 10 tolerates elective surgery; risk climbs steeply through the teens, and Child C or MELD above 20 means I postpone everything but urgent, life-saving surgery and involve a transplant center.1 I optimize ascites, encephalopathy, renal function, electrolytes and nutrition. I assess the heart and lungs for portopulmonary hypertension and hepatopulmonary syndrome with an echo. I treat bleeding guided by viscoelastic testing rather than correcting the INR. I use drugs that do not depend on the liver: cisatracurium, remifentanil, and reduced, titrated doses of everything else. I maintain hepatic blood flow by keeping MAP and cardiac output up and avoiding hypotension, hypoxia and high airway pressures.
Decision points and the "why"
- Risk scoring — Child-Pugh uses bilirubin, albumin, INR, ascites and encephalopathy; MELD uses bilirubin, INR, creatinine and sodium and predicts 30- and 90-day surgical mortality. Child A ~10%, B ~30%, C ~76–82% mortality for abdominal surgery in older series;2 MELD 12–15 carries about 25% and 16–20 about 44% 30-day mortality.3
- Rebalanced hemostasis — procoagulant and anticoagulant factors are both reduced; the INR overstates bleeding risk and these patients also thrombose. I do not give plasma to correct an INR before a procedure, because INR thresholds are not evidence-based and plasma raises portal pressure; for bleeding or high-risk procedures I aim for fibrinogen above 120 mg/dL and platelets above 50,000, using TEG or ROTEM to guide me.4
- Hyperdynamic circulation — high cardiac output and low SVR from nitric oxide and splanchnic vasodilation; vasoconstrictor response is blunted, so I start norepinephrine and vasopressin early.
- Hepatopulmonary syndrome — intrapulmonary shunting causes hypoxemia and platypnea; supplemental oxygen helps. Portopulmonary hypertension — a mean PA pressure above 35 mmHg needs pulmonary vasodilator therapy before transplant, and 45 mmHg or more is an absolute contraindication;5 I avoid hypoxia, hypercarbia and acidosis.
- Ascites — I drain large ascites before induction when it impairs ventilation, and when more than 5 L is removed I give albumin 6–8 g per liter removed to prevent post-paracentesis circulatory dysfunction.6
- Drugs — larger volume of distribution and lower albumin mean an initial dose that is normal or larger, with prolonged duration; I avoid benzodiazepines because they precipitate encephalopathy.3
- Full stomach — tense ascites and varices; I do a rapid sequence and place an orogastric tube gently.
The complication they will inject
During an umbilical hernia repair in a Child B patient the MAP falls to 55 after 2 L of ascites drains and the field oozes. I tell the surgeon, give albumin and norepinephrine, add vasopressin if needed, and send a gas, hemoglobin, ionized calcium and a TEG. If the TEG shows low fibrinogen I give cryoprecipitate; if the clot strength is weak, platelets; I reserve plasma for prolonged R time with active bleeding, because large-volume plasma raises portal pressure and worsens bleeding.4 Postoperatively I watch for hepatorenal syndrome, treated with albumin and vasoconstrictors such as terlipressin or norepinephrine, and for encephalopathy, treated with lactulose and rifaximin.
Pitfalls that cost points
- Correcting a pre-procedure INR with plasma.
- Proceeding with elective surgery in Child C without discussing whether to operate.
- Using benzodiazepines for premedication or sedation.
- Treating low SVR with fluid alone.
- Forgetting portopulmonary hypertension in the cirrhotic with dyspnea.
Rapid-why
Q: Why is cisatracurium preferred? A: Hofmann elimination is independent of the liver and kidney; rocuronium and vecuronium are prolonged.
Q: Why are these patients hyponatremic? A: Splanchnic vasodilation triggers ADH release and water retention; I correct no faster than 8 mEq/L per day because of osmotic demyelination.
Q: Why does the volatile choice matter little? A: Sevoflurane, desflurane and isoflurane all maintain hepatic blood flow; halothane is the one that reduces it.
Q: What is the risk of acetaminophen? A: It is safe in cirrhosis at a reduced ceiling of about 2–3 g per day3 and better than NSAIDs, which precipitate renal failure and bleeding.
Numbers to know
| Item | Value |
|---|---|
| MELD for elective surgery | < 10 acceptable; > 20 defer all but urgent surgery1 |
| Child-Pugh abdominal surgery mortality | A ~10%, B ~30%, C ~76–82%2 |
| Albumin with paracentesis | 6–8 g per L removed when > 5 L drained6 |
| Fibrinogen target (bleeding or high-risk procedure) | > 120 mg/dL; platelets > 50,0004 |
| Portopulmonary hypertension | mPAP > 35 treat first; ≥ 45 contraindicates transplant5 |
| Acetaminophen in cirrhosis | 2–3 g/day3 |
Links
- Liver transplantation (coming), Postoperative jaundice: is anesthesia the cause?, Massive hemorrhage and transfusion, Acute kidney injury (coming), Pulmonary hypertension and right ventricular failure (coming)
- AASLD practice guidance on management of ascites and hepatorenal syndrome (2021); AGA clinical practice update on perioperative risk in cirrhosis
Sources
- 1.AGA Clinical Practice Update: Surgical risk assessment and perioperative management in cirrhosis (MDedge summary) · American Gastroenterological Association, 2019 · mdedge.comMELD >20 or Child C: postpone all but urgent procedures until after transplant; use multiple scores (CTP, MELD, Mayo).
- 2.Non-Hepatic Abdominal Surgery in Patients with Cirrhotic Liver Disease (Table 2) · Journal of Gastrointestinal Surgery, 2018 · pmc.ncbi.nlm.nih.gov
- 3.Liver Cirrhosis Surgical Patient Management - Adult · Auckland District Health Board (NZSG), 2020 · nzsg.org.nzMELD 30-day mortality bands; benzodiazepines raise encephalopathy risk; paracetamol 2–3 g/day.
- 4.Coagulation in Cirrhosis (clinical practice update) · American Gastroenterological Association · gastro.org
- 5.Macitentan Improves Risk Categorization for Liver Transplant Mortality in Patients With Portopulmonary Hypertension: A PORTICO Study Post Hoc Analysis · Liver Transplantation, 2020 · pmc.ncbi.nlm.nih.govCites ILTS: mPAP >35 treat before transplant; mPAP ≥45 absolute contraindication.
- 6.Diagnosis and management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome · Cleveland Clinic Journal of Medicine, 2023 · ccjm.orgSummarizes AASLD 2021 guidance on albumin with large-volume paracentesis.
Facts on this page were checked against these sources on Oct 14, 2026. Guidelines change; confirm doses against current institutional protocols.